This page shows what was measured, who it was measured in, and what that does not settle.
What Triamcinolone Acetonide does in the body
XIPERE ® (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for the treatment of macular edema associated with uveitis.
From the FDA-approved label: Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisolone and triamcinolone are primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone acetonide possesses glucocorticoid activity typical of this class of drug, but with little or no mineralocorticoid activity.
Why people take it. XIPERE ® (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for the treatment of macular edema associated with uveitis.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · F446C597KA · read 2026-08-29
Its recorded molecular formula is C24H31FO6Tr.
US prescribing information · ea6ad429-967f-4f75-a33d-e06f849bee80 · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 112 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
…Waiting for a reviewer1 registered performance measure of this kind.
…Waiting for a reviewer7 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Pain
pain visual analogue scale; pain; pain intensity; shoulder pain and disability index; pain assessment; visual analog pain; pain assessed on the visual analogue scale; pain assessed on visual analog scale
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
1 registered performance measure of this kind.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
✗ The study did not show it
Who was studied
NCT03568318
How many people
1533
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
✗ The study did not show it
Who was studied
NCT00106132
How many people
1260
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change in central subfield mean macular thickness as a measurement of efficacy
✗ The study did not show it
Who was studied
NCT01774474
How many people
1127
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Lung Health Study II
✗ The study did not show it
Who was studied
NCT00000569
How many people
1116
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
NRS pain scores
✗ The study did not show it
Who was studied
NCT07347067
How many people
1036
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
NRS pain scores
✗ The study did not show it
Who was studied
NCT07347730
How many people
1036
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.1 registered measure of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.1 registered measure of this kind.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.8 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
pain visual analogue scale
pain
pain intensity
pain assessment
scores on the boston carpal tunnel questionnaire
visual analog pain
pain assessed on the visual analogue scale
pain assessed on visual analog scale
Measured
Things only a test, a scale or a device shows.
ocular inflammation
Meaningful
Things that change how a life goes, not only a number.
adverse events death and serious adverse events
shoulder pain and disability index
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (29)
central macular thickness
visual acuity baseline to 2 years
distribution of change in visual acuity baseline to 2 years
visual acuity
central subfield macular thickness
intraocular pressure
best corrected visual acuity
time to first new flare
treatment success
disabilities of the arm shoulder and hand
keloid recurrence
womac
responders
quinnell classification
shoulder function as measured by the quickdash
visual analogue scale
intraoperative bleeding
visual analog scale
mayo elbow
veteran rand 36 item health survey
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or…
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of XIPERE ® in pediatric patients have not been established.”
US prescribing information · ea6ad429-967f-4f75-a33d-e06f849bee80 · read 2026-08-30
On older people, the label states: “No overall differences in safety or effectiveness have been observed between elderly and younger patients following XIPERE ® administration.”
US prescribing information · ea6ad429-967f-4f75-a33d-e06f849bee80 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary There are no adequate and well-controlled studies with XIPERE ® in pregnant women to inform drug-associated risks.”
US prescribing information · ea6ad429-967f-4f75-a33d-e06f849bee80 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary It is not known whether ocular administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.”
US prescribing information · ea6ad429-967f-4f75-a33d-e06f849bee80 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (9)
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Topical
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Sold as cream, lotion, ointment, injectable, given by the topical, injection, nasal route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Triamcinolone Acetonide appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1784 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Topical
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
333 products list this as an active ingredient in the United States drug directory. 297 of them contain it and nothing else.
FDA National Drug Code directory · 72162-1832 · read 2026-08-29
They are sold as aerosol, spray, cream, injection, powder, for suspension, extended release, injection, suspension, lotion and ointment, taken dental, intra-arterial, intra-articular and intralesional.
FDA National Drug Code directory · 72162-1832 · read 2026-08-29
The regulator's established pharmacologic class for it is corticosteroid hormone receptor agonists [moa] and corticosteroid [epc].
FDA National Drug Code directory · 72162-1832 · read 2026-08-29
249 published labels name it as an active ingredient. 214 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · b909659e-8dd5-4652-89f4-c4d6b741a855 · read 2026-08-29
Those labels are classed as human otc drug and human prescription drug.
US prescribing information · b909659e-8dd5-4652-89f4-c4d6b741a855 · read 2026-08-29
Xipere is ophthalmic at 3 DOSAGE FORMS AND STRENGTHS Injectable suspension: triamcinolone acetonide 40 mg/mL suspension in a single-dose glass vial for use with the supplied SCS Microinjector ® ., recorded as fda label in effect 2025-10-08 in the United States.
US prescribing information · ea6ad429-967f-4f75-a33d-e06f849bee80 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (10)
Q2
What did Triamcinolone Acetonide's largest trial (1260 people) and its longest (13 years) measure?
1260 people in Triamcinolone Acetonide's largest registered study, 13 years in its longest registered window, measuring Concentration of Triamcinolone Acetonide in Synovial Fluid. ClinicalTrials.gov · 2026-09-01
75 phase2, 70 na, 63 phase3, 60 phase4, 23 phase1, 6 na or unstated, 4 early phase1; NCT02025023; 2026-07. Last human test completed 2026, NCT06176248.
Interpretation These counts include studies where Triamcinolone Acetonide was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
75
na
70
phase3
63
phase4
60
phase1
23
na or unstated
6
2 more recorded rows
early phase1
4
Last recorded human testNCT06176248
2026-06-06
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Triamcinolone Acetonide shown biomarker?
safety (2), futility/efficacy (5), accrual/recruitment (17), funding/business (2) and other (11): Triamcinolone Acetonide's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"patient's recruitment too difficult"; 37 of 276 registered studies
Show the evidence
Trial
NCT00344942
terminated; "patient's recruitment too difficult"
NCT00588354
terminated; "Targeted enrollment was not reached."
NCT00742846
withdrawn; "No enrollment"
NCT00924508
terminated; "Loss of Funding"
NCT01045694
terminated; "Unable to acquire additional funding needed to continue this study."
NCT01095809
terminated; "New intraocular steroid in the market. Recruitment no longer ethical."
14 further recorded trials
NCT01222871
terminated; "not enough particpants"
NCT01688362
terminated; "Did not meet target enrollment deadlines."
NCT01720056
terminated; "Objective of study achieved after interim analysis."
NCT01898806
terminated; "The PI left the Columbia University Medical Center. Study was not Completed."
NCT01978301
terminated; "Temporary hold on recruitment during staff changes at the site"
NCT02120261
terminated; "lack of activity, Primary researcher moved to another institution"
NCT02191748
terminated; "Principal investigator made the decision to close study and not submit a renewal. Lack of fixed research personnel to carry out the study effectively."
NCT02399800
terminated; "Low enrollment"
NCT02519738
terminated; "enrollment difficulties"
NCT02592629
terminated; "Lack of time to enroll due to additional responsibilities of the PI and research coordinator."
NCT02655523
withdrawn; "lack of recruitment"
NCT02980874
terminated; "Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent."
NCT03166761
terminated; "recruitment and staffing"
NCT03203447
terminated; "The early termination is due to the results obtained from the sister study, SAPPHIRE (CLS1003-301), which did not meet the 8-week primary efficacy endpoint."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Triamcinolone Acetonide used 1mg triamcinolone acetonide — over how long?
Which of adverse events, adverse events death and serious adverse events and bcva did Triamcinolone Acetonide's trials measure?
adverse events, adverse events death and serious adverse events and bcva lead 40 outcome terms across Triamcinolone Acetonide's trials. ClinicalTrials.gov · 2026-09-01
Interpretation visual acuity, pain visual analogue scale, ocular inflammation, central subfield macular thickness, intraocular pressure and best corrected visual acuity follow.
Show the evidence
central macular thickness
1
visual acuity baseline to 2 years
1
distribution of change in visual acuity baseline to 2 years
1
visual acuity
1
pain visual analogue scale
1
ocular inflammation
1
14 more recorded rows
central subfield macular thickness
1
intraocular pressure
1
best corrected visual acuity
1
time to first new flare
1
adverse events death and serious adverse events
1
pain
1
pain intensity
1
treatment success
1
shoulder pain and disability index
1
disabilities of the arm shoulder and hand
1
pain assessment
1
keloid recurrence
1
womac
1
responders
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Triamcinolone Acetonide's 30 ongoing trials reports first?
Incidence of adverse events; Change in Pain Intensity Measure (mm); latest 2030-03
Show the evidence
Trial
NCT04094298
"Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease"; n 65; "Incidence of adverse events"; 2025-01-31
NCT04126824
"Effect of Addition of Steroids on Duration of Analgesia"; n 28; "Change in Pain Intensity Measure (mm)"; 2027-08-02
NCT04207931
"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study"; n 250; "Central Scalp Alopecia Photographic Scale in African American Women"; 2027-03
NCT04469075
"Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields"; n 48; "Number of patients without grade 2 or higher skin toxicity"; 2027-07
NCT04641351
"Corticosteroid Meniscectomy Randomized Trial"; n 150; "Change in Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline and 3 months."; 2027-08-01
NCT04642352
"Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough"; n 50; "Change in score on the Leicester Cough Questionnaire"; 2026-10
14 further recorded trials
NCT04744675
"Peripheral Nerve Injections for CRPS"; n 50; "Recruitment"; 2025-06
NCT05331664
"Dropless Pars Plana Vitrectomy Study"; n 168; "Mean anterior chamber cell"; 2027-01-30
NCT05535738
"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation"; n 45; "To collect and evaluate single-cell multiomics data (RNAseq, CITEseq, TCRseq)"; 2027-12-31
NCT05806021
"The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis"; n 327; "WOMAC Function"; 2026-02
NCT05906433
"Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis"; n 75; "Injection for Knee Pain"; 2025-12-01
NCT06327581
"Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata"; n 88; "hair regrowth improvement assessed by SALT score and percaentage of hair growth"; 2026-12-30
NCT06401317
"Corticosteroid Against Saline Injections for Thumb Osteoarthritis (CASITOA)"; n 40; "Rate of participant recruitment"; 2028-12-31
NCT06407180
"Efficacy of Intra-Articular Corticosteroid Injections on Clinical Outcomes in Patients With Operative Distal Radius Fractures"; n 58; "Patient-Rated Wrist Evaluation Score"; 2026-12-31
NCT06641206
"Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain"; n 70; "Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection."; 2025-03
NCT06748404
"TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus"; n 28; "To evaluate the efficacy of TriCalm Hydrogel® in reducing the severity of immunotherapy-related pruritus."; 2028-12
NCT06810752
"Thyme Honey for Management of Oral Lichen Planus"; n 30; "VAS score assessement"; 2025-03
NCT06814288
"The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment"; n 20; "Japan Scar Workshop Scar Scale (JSS)"; 2025-03-01
NCT06935877
"Additional Effect of Steroid on Hyaluronic Acid in Subdeltoid Bursitis"; n 60; "Shoulder Pain and Disability Index"; 2026-06-30
NCT07006168
"Effects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation"; n 56; "Pain as measured by Numerical Patient Reported Scale (NRPS)"; 2027-07-31
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which 67 trials of Triamcinolone Acetonide posted no result?
Posted no result
67 of 67 completed trials
Registrations
NCT00000569, NCT00369863, NCT00373282, NCT00106132, NCT00005922 and NCT00105404, and 61 more
Completion dates
oldest 1999-05; newest 2024-06-30
Show the evidence
Trial
NCT00000569
1999-05
NCT00369863
2003-06
NCT00373282
2003-06
NCT00106132
2005-11
NCT00005922
2006-07
NCT00105404
2006-10-30
14 further recorded trials
NCT00100009
2006-12-20
NCT00140803
2007-01
NCT00071227
2007-08-15
NCT00789971
2008-04
NCT00101764
2008-05-20
NCT00874744
2008-10
NCT00908817
2009-05
NCT00915837
2009-05
NCT00309192
2009-07
NCT00411333
2009-07
NCT07702474
2009-12-01
NCT01109446
2011-10
NCT00583271
2012-12
NCT02310295
2012-12
Q9
At the median, Triamcinolone Acetonide's trials enrolled 51.5 people — anything larger?
Median enrolment
51.5
Largest enrolment
1260
Registered trials counted
274
Q10
What do 1784 spontaneous reports say about Triamcinolone Acetonide — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Triamcinolone Acetonide appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1784 reaction mentions were counted: adrenal insufficiency 257; drug interaction 252; condition aggravated 239; cushing's syndrome 222. open-targets-adr · CHEMBL1504 · 2026-06-24
Show the evidence
adrenal insufficiency
257
drug interaction
252
condition aggravated
239
cushing's syndrome
222
endophthalmitis
154
visual acuity reduced
154
4 more recorded rows
synovitis
130
macular degeneration
126
obesity
126
intraocular pressure increased
124
recorded 2026-06-24 · last checked 2026-09-04
Q11
What is recorded about Triamcinolone Acetonide and autophagy?
"The system concurrently encapsulated curcumin (Cur), an autophagy activator, and triamcinolone acetonide (TA), synergistically inducing fibroblast apoptosis by upregulating autophagic activity. <i>In vitro</i> studies demonstrated that active MNs achieved efficient drug penetration within isolated scar tissue." — where Triamcinolone Acetonide and autophagy appear together. Europe PMC · pathway abstract search · 2025-05-21
autophagy; PMID 40698123, 34306337
Show the evidence
autophagy
PMID 40698123
"The system concurrently encapsulated curcumin (Cur), an autophagy activator, and triamcinolone acetonide (TA), synergistically inducing fibroblast apoptosis by upregulating autophagic activity. <i>In vitro</i> studies demonstrated that active MNs achieved efficient drug penetration within isolated scar tissue."
PMID 34306337
"The improvement of urethral fibrosis by TA combined with 5-FU treatment was blocked by miR-192-5p inhibitor. miR-192-5p mediated the improvement of urethral scar by triamcinolone acetonide combined with 5-FU by directly targeting ATG7, which is marker gene of autophagy."
recorded 2025-05-21 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 8 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.